Close Menu


Laboratories are continuing to experience supply chain interruptions and are facing significant staffing shortages, the report found.

The study currently tests 28,000 people every two weeks and will expand to 150,000 by October, with the aim to increase to 400,000 people across the country.

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

Although people have greater access to personalized drugs and tests than ever before, a survey by GenomeWeb and the PMC shows public awareness isn't improving.  

There are signs that doctors may be moving away from experimental precision therapy options in favor of immunotherapy and the chance at longer survival.

In a survey of 132 oncologists, Medscape tracked how they are using next-generation sequencing and what they think of its clinical utility.